ClinicalTrials.gg
CompletedNCT00098293MERITUpdated Oct 9, 2013Results posted

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

A Phase 3 interventional study of Maraviroc + Zidovudine/Lamivudine and Efavirenz + Zidovudine/Lamivudine in HIV-1, sponsored by ViiV Healthcare. Completed at 144 sites in 14 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2013-10-09.

Primary conditionAcquired Immunodeficiency Syndrome(the registry's first term)UnverifiedIs this wrong?The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
916
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The goal of this study is to compare the safety and efficacy of maraviroc (UK-427,857) versus efavirenz, when each are combined with two other antiretroviral agents, in patients who are previously naive to antiretroviral therapy. This study will involve approximately 200 centers from around the world to achieve a total randomized subject population of 1071 subjects. Patients will be randomly assigned to one of three groups: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily), Maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily) or efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily). The study will enroll over approximately an 18 month period (5 months Phase 2b run-in, 13 months Phase 3) with 96 weeks of treatment. This may be extended for an additional 3 years depending on the results at 96 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 48 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24, 48 and 96. A computerized tomography (CT) scan will also be performed, at selected centers, at study entry and week 96. Patients will be asked to complete a symptom distress questionnaire at study entry, weeks 12, 24, 48 and 96.

02

Conditions studied

  • HIV-1

Browse trials for

Keywords

  • Aids
  • HIV
03

In context

Acquired Immunodeficiency Syndrome Unverified

3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 307 are open to participants now.

This study's enrollment of 916 is above the median of 96 across 2,252 interventional studies indexed under Acquired Immunodeficiency Syndrome.

Browse Acquired Immunodeficiency Syndrome studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)
  • -1 RNA viral load of greater than or equal to 2, 000 copies/mL
  • A negative urine pregnancy test at the baseline visit for Women of Child Bearing Potential ()
  • Effective barrier for WOCBP and males

Exclusion criteria

Exclusion Criteria:

  • Suspected or documented active, untreated -1 related opportunistic infection (OI) or other condition requiring acute therapy
  • Treatment for an active opportunistic infection, or unexplained temperature >38.5 degrees Celsius for 7 consecutive days
  • Prior treatment with efavirenz, zidovudine or lamivudine or with any other antiretroviral therapy for more than 14 days at any time
  • Active alcohol or substance abuse sufficient, in the Investigator's judgment, to prevent adherence to study medication and/or follow up
  • Lactating women, or planned pregnancy during the trial period
  • Suspected primary (acute) HIV-1 infection
  • Previous therapy with a potentially myelosuppressive, neurotoxic, hepatotoxic and/or cytotoxic agent within 30 days prior to randomization or the expected need for such therapy during the study period
  • Documented or suspected acute hepatitis or pancreatitis within 30 days prior to randomization
  • Significantly elevated liver enzymes or cirrhosis
  • Significant neutropenia, anemia or thrombocytopenia
  • Malabsorption or an inability to tolerate oral medications
  • Symptomatic postural hypotension or severe cardiovascular or cerebrovascular disease
  • Certain medications
  • Genotypic or phenotypic resistance to efavirenz, zidovudine or lamivudine
  • X4- or dual/mixed-tropic virus or repeated assay failure
  • Any other clinical condition that, in the Investigator's judgement, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
916 participants (actual)

Study arms

  • Experimental
    1

    Drug: Maraviroc + Zidovudine/Lamivudine

  • Active comparator
    3

    Drug: Efavirenz + Zidovudine/Lamivudine

  • Experimental
    2

    Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz

    Drug: Maraviroc (UK-427,857) + Zidovudine/Lamivudine

Interventions

  • DrugMaraviroc + Zidovudine/Lamivudine

    Drug pages: Maraviroc · Zidovudine · Lamivudine

    maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)

  • DrugEfavirenz + Zidovudine/Lamivudine

    Drug pages: Efavirenz · Zidovudine · Lamivudine

    efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)

  • DrugMaraviroc (UK-427,857) + Zidovudine/Lamivudine

    Drug page: Maraviroc

    maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population

    Time frame: Week 48

  2. Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population

    Percentage of participants with viral load of less than 400 copies/mL and less than 50 copies/mL of HIV-1 RNA were not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 Analyzed Using Logistic Regression

    Time frame: Week 48

  2. Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 Analyzed Using Logistic Regression

    Time frame: Week 96

  3. Change From Baseline in Log 10-transformed Plasma Viral Load (HIV-1 RNA) Levels at Week 48 and 96

    Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

    Time frame: Baseline, Week 48, Week 96

  4. Time-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels

    TAD from baseline was calculated as area under the curve (AUC) of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose. Data not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.

    Time frame: Baseline up to Week 48 and Week 96

  5. Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 48 and 96

    Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose.

    Time frame: Baseline, Week 48, Week 96

  6. Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 48 and 96

    Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose. Change from baseline in lymphocyte CD8 count at Week 48 and 96 was not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.

    Time frame: Baseline, Week 48, Week 96

  7. Time to Virologic Failure

    Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up \[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL(2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL(2 consecutive visits);failure if level \>=400 copies/mL(2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.

    Time frame: Week 48, Week 96

  8. Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48

    Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 48 visit. Treatment failure: discontinuation due to insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as last on treatment assessment.

    Time frame: Baseline, time of failure through Week 48

  9. Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 96

    Number of participants per tropism status (R5, X4, DM, or NR/NP) at baseline and time of treatment failure analyzed through week 96 visit. Treatment failure defined as insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as BLQ. The assessment for time of treatment failure was defined as last on treatment assessment.

    Time frame: Baseline, time of failure through Week 96

  10. Number of Participants With Phenotypic Resistance at Time of Treatment Failure Through Week 48 and 96

    Phenotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) assessed at screening by Monogram Bioscience PhenoSense genotype (MBPSGT) assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Phenotypic resistance to maraviroc was assumed in maraviroc treatment failures with X4-using virus and in R5 maraviroc treatment failures using Monogram Bioscience PhenoSense Entry Assay. Phenotypic resistance to zidovudine, lamivudine, efavirenz and maraviroc at time of failure was summarized.

    Time frame: Screening, time of failure through Week 48, Week 96

  11. Number of Participants With NRTI Associated Mutations at Time of Treatment Failure Through Week 48 and 96

    Genotypic resistance to NRTIs was assessed by identification of relevant mutations at screening using MBPSGT assay and repeated for all participants with HIV-1 viral load more than 500 copies/mL at treatment failure through week 48 and week 96. Following mutations associated with NRTIs were summarized at time of failure: Any zidovudine/lamivudine (Zid/Lam), Any thymidine analogue-associated mutation (TAM), methionine (M) to valine/isoleucine (V/I) substitution at residue (r) 184 (M184V/I), lysine (K) to arginine (R) substitution at residue 65 (K65R) and any other NRTI mutations.

    Time frame: Screening, time of failure through Week 48, Week 96

  12. Number of Participants With Efavirenz Associated Mutations at Time of Treatment Failure Through Week 48 and 96

    Genotypic resistance: mutations at screening by MBPSGT assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Efavirenz mutation:lysine to aspargine at r103(K103N);tyrosine to cysteine/isoleucine at r181(Y181C/I);tyrosine to cysteine/leucine/histidine at r188(Y188C/L/H);glycine to alanine/serine at r190(G190A/S);valine to alanine to r106(V106A);leucine to isoleucine at r100(L100I);alanine to glycine at r98(A98G);lysine to glutamic acid at r101(K101E);valine to isoleucine at r108(V108I);proline to histidine at r225(P225H);methionine to leucine at r230(M230L).

    Time frame: Screening, time of failure through Week 48, Week 96

  13. Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL at Week 48 and Week 96 by Overall Susceptibility Score (OSS) at Screening

    Association between baseline resistance and virological response was assessed as percentage of participants with HIV-1RNA levels less than 50 copies/mL by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility.

    Time frame: Baseline, Week 48, Week 96

Other outcomes

  1. Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 96

    Time frame: Week 96

07

Results

Posted Oct 5, 2012
Limitations and caveats
Following DSMB decision to discontinue maraviroc 300 mg once daily, inferential statistical analyses was performed between maraviroc 300 mg twice daily and efavirenz 600 mg once daily only. Data at Week 24 was not analyzed as planned in protocol.

Participant flow

Double-blind (DB) Phase
Participant flow — Double-blind (DB) Phase
MilestoneMaraviroc Once Daily + CBV (DB)Maraviroc Twice Daily + CBV (DB and OL)Efavirenz Once Daily + CBV (DB and OL)Maraviroc Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (SP)
Started17736837200
Treated17436036100
Completed020220200
Not completed17716617000
Withdrew: Adverse event14276000
Withdrew: Pregnancy07900
Withdrew: Participant defaulted11403600
Withdrew: Lack of efficacy11643000
Withdrew: Death12200
Withdrew: Randomized, not treated381100
Withdrew: Protocol violation2182200
Withdrew: Terminated by sponsor1350000
Between DB and OL Phase
Participant flow — Between DB and OL Phase
MilestoneMaraviroc Once Daily + CBV (DB)Maraviroc Twice Daily + CBV (DB and OL)Efavirenz Once Daily + CBV (DB and OL)Maraviroc Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (SP)
Started020220200
Completed020219900
Not completed00300
Withdrew: Did not enter open-label phase00300
Open-label (OL) Phase
Participant flow — Open-label (OL) Phase
MilestoneMaraviroc Once Daily + CBV (DB)Maraviroc Twice Daily + CBV (DB and OL)Efavirenz Once Daily + CBV (DB and OL)Maraviroc Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (SP)
Started02021991300
Completed0177158650
Not completed02541650
Withdrew: Adverse event03760
Withdrew: Lack of efficacy072200
Withdrew: Pregnancy01030
Withdrew: Protocol violation0613160
Withdrew: Participant defaulted0616200
Withdrew: Death02300
Supplemental Phase (SP)
Participant flow — Supplemental Phase (SP)
MilestoneMaraviroc Once Daily + CBV (DB)Maraviroc Twice Daily + CBV (DB and OL)Efavirenz Once Daily + CBV (DB and OL)Maraviroc Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (SP)
Started0000127
Completed000094
Not completed000033
Withdrew: Death00001
Withdrew: Lost to follow-up00002
Withdrew: Withdrawal by subject00008
Withdrew: Other000022

Outcome measures

PrimaryPercentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population
Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) Population
Percentage of participantsMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Less than 400 copies/mL61.570.673.1
Less than 50 copies/mL55.865.369.3
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -3.0
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -4.2
PrimaryPercentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population

Percentage of participants with viral load of less than 400 copies/mL and less than 50 copies/mL of HIV-1 RNA were not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) Population
Percentage of participantsMaraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Less than 400 copies/mL75.0078.27
Less than 50 copies/mL70.0074.44
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -4.1
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -4.4
SecondaryPercentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 Analyzed Using Logistic Regression
Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 Analyzed Using Logistic Regression
Percentage of participantsMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Less than 400 copies/mL61.570.673.1
Less than 50 copies/mL55.865.369.3
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Regression, Logistic · p = 0.4485 · Odds ratio (or): 0.88 · 95% CI 0.64 to 1.22
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Regression, Logistic · p = 0.2724 · Odds ratio (or): 0.84 · 95% CI 0.61 to 1.15
SecondaryPercentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 Analyzed Using Logistic Regression
Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 Analyzed Using Logistic Regression
Percentage of participantsMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Less than 400 copies/mL52.961.464.5
Less than 50 copies/mL48.356.962.6
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Regression, Logistic · p = 0.3943 · Odds ratio (or): 0.88 · 95% CI 0.65 to 1.19
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Regression, Logistic · p = 0.1289 · Odds ratio (or): 0.79 · 95% CI 0.59 to 1.07
SecondaryChange From Baseline in Log 10-transformed Plasma Viral Load (HIV-1 RNA) Levels at Week 48 and 96

Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

Time frame:
Baseline, Week 48, Week 96
Reported as:
Mean · log10 copies/mL
Change From Baseline in Log 10-transformed Plasma Viral Load (HIV-1 RNA) Levels at Week 48 and 96
log10 copies/mLMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Baseline4.899 ± 0.62734.851 ± 0.65114.857 ± 0.6156
Change at Week 48-2.665 ± 0.9454-2.240 ± 1.484-2.347 ± 1.455
Change at Week 96-2.565 ± 0.9731-1.961 ± 1.575-2.053 ± 1.564
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · ANCOVA · p = 0.2741 · Ls mean difference: 0.118 · 95% CI -0.094 to 0.329
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · ANCOVA · p = 0.3899 · Ls mean difference: 0.100 · 95% CI -0.128 to 0.328
SecondaryTime-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels

TAD from baseline was calculated as area under the curve (AUC) of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose. Data not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.

Time frame:
Baseline up to Week 48 and Week 96
Reported as:
Least squares mean · log10 copies/mL
Time-Averaged Difference (TAD) in log10-transformed HIV-1 RNA Levels
log10 copies/mLMaraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Week 48-2.152 ± 0.0713-2.262 ± 0.0714
Week 96-1.945 ± 0.0798-2.034 ± 0.0800
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · ANCOVA · p = 0.2693 · Ls mean difference: 0.111 · 95% CI -0.086 to 0.307
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · ANCOVA · p = 0.4270 · Ls mean difference: 0.089 · 95% CI -0.131 to 0.309
SecondaryChange From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 48 and 96

Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose.

Time frame:
Baseline, Week 48, Week 96
Reported as:
Mean · cells per microliter (cells/µL)
Change From Baseline in Lymphocyte Cluster of Differentiation 4 (CD4) Count at Week 48 and 96
cells per microliter (cells/µL)Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Baseline274.1 ± 175.45264.70 ± 153.508271.87 ± 133.491
Change at Week 48172.50 ± 205.561169.53 ± 134.409143.52 ± 124.931
Change at Week 96183.75 ± 166.454206.31 ± 152.682171.50 ± 149.163
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · ANCOVA · p = 0.0075 · Ls mean difference: 26.34 · 95% CI 7.04 to 45.63
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · ANCOVA · p = 0.0020 · Ls mean difference: 35.44 · 95% CI 13.02 to 57.86
SecondaryChange From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 48 and 96

Baseline value calculated as the average of pre-dose measurements collected at screening and immediately pre-dose. Change from baseline in lymphocyte CD8 count at Week 48 and 96 was not analyzed for participants originally randomized to maraviroc once daily arm since after termination, focus was shifted from efficacy and safety to only safety as reflected in the abbreviated set of efficacy measures noted in the amended planned analysis.

Time frame:
Baseline, Week 48, Week 96
Reported as:
Mean · cells/µL
Change From Baseline in Lymphocyte Cluster of Differentiation 8 (CD8) Count at Week 48 and 96
cells/µLMaraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Baseline938.80 ± 503.392935.78 ± 476.607
Change at Week 4838.34 ± 397.503-126.83 ± 374.494
Change at Week 9620.74 ± 412.081-150.27 ± 389.996
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · ANCOVA · p = <0.0001 · Ls mean difference: 166.29 · 95% CI 117.13 to 215.46
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · ANCOVA · p = <0.0001 · Ls mean difference: 172.22 · 95% CI 122.21 to 222.23
SecondaryTime to Virologic Failure

Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up \[LTFU\];new anti-retroviral drug added \[except background drug change to drug of same class\];or on open label for early non-response or rebound). Failure:at Time 0 if level not \<400 copies/mL(2 consecutive visits) before events or last available visit;at time of earliest event if level \<400 copies/mL(2 consecutive visits);failure if level \>=400 copies/mL(2 consecutive visits) or 1 visit \>=400 copies/mL followed by permanent discontinuation of drug or LTFU.

Time frame:
Week 48, Week 96
Reported as:
Median · days
Time to Virologic Failure
daysMaraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Week 48NA (354 to NA)NA (364 to NA)
Week 96NA (NA to NA)NA (691 to NA)
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Log Rank · p = 0.5874 · Hazard ratio (hr): 1.10 · 95% CI 0.83 to 1.45
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Log Rank · p = 0.4811 · Hazard ratio (hr): 1.10 · 95% CI 0.86 to 1.40
SecondaryNumber of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48

Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} \[R5\], C-X-C chemokine receptor type 4 {CXCR4} \[X4\], Dual/mixed \[DM\], or Non-reportable/Non-phenotypable \[NR/NP\]) at baseline and time of treatment failure analyzed through week 48 visit. Treatment failure: discontinuation due to insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as last on treatment assessment.

Time frame:
Baseline, time of failure through Week 48
Reported as:
Number · participants
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48
participantsMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Baseline: R5; Treatment failure: R55116
Baseline: R5; Treatment failure: X4000
Baseline: R5; Treatment failure: DM3100
Baseline: R5; Treatment failure: NR/NP554
Baseline: DM; Treatment failure: R5010
Baseline: DM; Treatment failure: X4020
Baseline: DM; Treatment failure: DM540
Baseline: DM; Treatment failure: NR/NP000
SecondaryNumber of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 96

Number of participants per tropism status (R5, X4, DM, or NR/NP) at baseline and time of treatment failure analyzed through week 96 visit. Treatment failure defined as insufficient clinical response. Tropism result was censored for participants with viral load \<500 copies/mL at time of treatment failure categorized as BLQ. The assessment for time of treatment failure was defined as last on treatment assessment.

Time frame:
Baseline, time of failure through Week 96
Reported as:
Number · participants
Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 96
participantsMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Baseline: R5; Treatment failure: R591410
Baseline: R5; Treatment failure: X4010
Baseline: R5; Treatment failure: DM4110
Baseline: R5; Treatment failure: NR/NP675
Baseline: DM; Treatment failure: R5011
Baseline: DM; Treatment failure: X4020
Baseline: DM; Treatment failure: DM540
Baseline: DM; Treatment failure: NR/NP000
Baseline: NR/NP; Treatment failure: R5010
Baseline: NR/NP; Treatment failure: X4000
Baseline: NR/NP; Treatment failure: DM000
Baseline: NR/NP; Treatment failure: NR/NP010
SecondaryNumber of Participants With Phenotypic Resistance at Time of Treatment Failure Through Week 48 and 96

Phenotypic resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) assessed at screening by Monogram Bioscience PhenoSense genotype (MBPSGT) assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Phenotypic resistance to maraviroc was assumed in maraviroc treatment failures with X4-using virus and in R5 maraviroc treatment failures using Monogram Bioscience PhenoSense Entry Assay. Phenotypic resistance to zidovudine, lamivudine, efavirenz and maraviroc at time of failure was summarized.

Time frame:
Screening, time of failure through Week 48, Week 96
Reported as:
Number · participants
Number of Participants With Phenotypic Resistance at Time of Treatment Failure Through Week 48 and 96
participantsMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Resistance to Zidovudine: Week 48 (n= 20, 43, 15)000
Resistance to Lamivudine: Week 48 (n= 20, 43, 15)14273
Resistance to Efavirenz: Week 48 (n= 20, 43, 15)007
Resistance to Maraviroc: Week 48 (n= 20, 43, 15)NA12NA
Resistance to Zidovudine: Week 96 (n= 27, 55, 23)000
Resistance to Lamivudine: Week 96 (n= 27, 55, 23)20338
Resistance to Efavirenz: Week 96 (n= 27, 55, 23)0013
Resistance to Maraviroc: Week 96 (n= 27, 55, 23)NANANA
SecondaryNumber of Participants With NRTI Associated Mutations at Time of Treatment Failure Through Week 48 and 96

Genotypic resistance to NRTIs was assessed by identification of relevant mutations at screening using MBPSGT assay and repeated for all participants with HIV-1 viral load more than 500 copies/mL at treatment failure through week 48 and week 96. Following mutations associated with NRTIs were summarized at time of failure: Any zidovudine/lamivudine (Zid/Lam), Any thymidine analogue-associated mutation (TAM), methionine (M) to valine/isoleucine (V/I) substitution at residue (r) 184 (M184V/I), lysine (K) to arginine (R) substitution at residue 65 (K65R) and any other NRTI mutations.

Time frame:
Screening, time of failure through Week 48, Week 96
Reported as:
Number · participants
Number of Participants With NRTI Associated Mutations at Time of Treatment Failure Through Week 48 and 96
participantsMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Any Zid/Lam Mutation: Week 48 (n= 20, 43, 15)14273
Any TAM Mutation: Week 48 (n= 20, 43, 15)160
K65R Mutation: Week 48 (n= 20, 43, 15)010
M184V/I Mutation: Week 48 (n= 20, 43, 15)14273
Other NRTI Mutation: Week 48 (n= 20, 43, 15)010
Any Zid/Lam Mutation: Week 96 (n= 27, 55, 23)20338
Any TAM Mutation: Week 96 (n= 27, 55, 23)362
K65R Mutation: Week 96 (n= 27, 55, 23)010
M184V/I Mutation: Week 96 (n= 27, 55, 23)20338
Other NRTI Mutation: Week 96 (n= 27, 55, 23)010
SecondaryNumber of Participants With Efavirenz Associated Mutations at Time of Treatment Failure Through Week 48 and 96

Genotypic resistance: mutations at screening by MBPSGT assay, repeated if viral load \>500 copies/mL at treatment failure through week 48, 96. Efavirenz mutation:lysine to aspargine at r103(K103N);tyrosine to cysteine/isoleucine at r181(Y181C/I);tyrosine to cysteine/leucine/histidine at r188(Y188C/L/H);glycine to alanine/serine at r190(G190A/S);valine to alanine to r106(V106A);leucine to isoleucine at r100(L100I);alanine to glycine at r98(A98G);lysine to glutamic acid at r101(K101E);valine to isoleucine at r108(V108I);proline to histidine at r225(P225H);methionine to leucine at r230(M230L).

Time frame:
Screening, time of failure through Week 48, Week 96
Reported as:
Number · participants
Number of Participants With Efavirenz Associated Mutations at Time of Treatment Failure Through Week 48 and 96
participantsMaraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
L100I Mutation: Week 48 (n= 43, 15)00
K103N Mutation: Week 48 (n= 43, 15)06
V106M Mutation: Week 48 (n= 43, 15)00
V108I Mutation: Week 48 (n= 43, 15)10
Y181C/I Mutation: Week 48 (n= 43, 15)00
Y188L Mutation: Week 48 (n= 43, 15)00
G190S/A Mutation: Week 48 (n= 43, 15)01
P225H Mutation: Week 48 (n= 43, 15)00
L100I Mutation: Week 96 (n= 55, 23)00
K103N Mutation: Week 96 (n= 55, 23)012
V106M Mutation: Week 96 (n= 55, 23)01
V108I Mutation: Week 96 (n= 55, 23)11
Y181C/I Mutation: Week 96 (n= 55, 23)00
Y188L Mutation: Week 96 (n= 55, 23)00
G190S/A Mutation: Week 96 (n= 55, 23)02
P225H Mutation: Week 96 (n= 55, 23)01
SecondaryPercentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL at Week 48 and Week 96 by Overall Susceptibility Score (OSS) at Screening

Association between baseline resistance and virological response was assessed as percentage of participants with HIV-1RNA levels less than 50 copies/mL by OSS at screening. OSS categorized as 0, 1, 2, \>3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility.

Time frame:
Baseline, Week 48, Week 96

No measurements were reported for this outcome.

Other pre-specifiedPercentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 96
Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 96
Percentage of participantsMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Less than 400 copies/mL52.961.464.5
Less than 50 copies/mL48.356.962.6
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -3.2
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -5.8
Post-hocPercentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants

Percentage of participants with HIV-1 RNA levels of less than 400 copies/mL and less than 50 copies/mL were not analyzed for maraviroc once daily, then twice daily arm in order to avoid misinterpretation due to possible bias due to the fact that only a non-random sample of participants in the terminated arm were re-assayed with ESTA.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 48 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants
Percentage of participantsMaraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Less than 400 copies/mL73.372.3
Less than 50 copies/mL68.568.3
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: 0.6
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -0.2
Post-hocPercentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants

Percentage of participants with HIV-1 RNA levels of less than 400 copies/mL and less than 50 copies/mL were not analyzed for maraviroc once daily, then twice daily arm in order to avoid misinterpretation due to possible bias due to the fact that only a non-random sample of participants in the terminated arm were re-assayed with ESTA.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA Levels of Less Than 400 Copies/mL and Less Than 50 Copies/mL at Week 96 for Enhanced Sensitivity Trofile Assay (ESTA) R5 Participants
Percentage of participantsMaraviroc Twice Daily + CBV (DB)Efavirenz Once Daily + CBV (DB)
Less than 400 copies/mL64.064.4
Less than 50 copies/mL58.862.7
Statistical analysis
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -0.4
  • Maraviroc Twice Daily + CBV (DB) vs Efavirenz Once Daily + CBV (DB) · Difference in percentage: -3.9

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)—47/174 (27%)151/174 (86.8%)
Maraviroc Twice Daily + CBV (DB and OL)—77/360 (21.4%)319/360 (88.6%)
Efavirenz Once Daily + CBV (DB and OL)—82/361 (22.7%)327/361 (90.6%)
Maraviroc Twice Daily + CBV (SP)—4/127 (3.1%)0/127 (0%)
Most frequent serious events
Showing 10 of 211
Most frequent serious events
EventMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB and OL)Efavirenz Once Daily + CBV (DB and OL)Maraviroc Twice Daily + CBV (SP)
AnaemiaBlood and lymphatic system disorders6/1747/3606/3610/127
PyrexiaGeneral disorders4/1744/3605/3610/127
PregnancyPregnancy, puerperium and perinatal conditions3/1745/3608/3610/127
NeutropeniaBlood and lymphatic system disorders3/1742/3602/3610/127
PneumoniaInfections and infestations1/1743/3605/3610/127
DiarrhoeaGastrointestinal disorders2/1742/3600/3610/127
Chest painGeneral disorders2/1740/3600/3610/127
Jaw fractureInjury, poisoning and procedural complications2/1740/3600/3610/127
Suicide attemptPsychiatric disorders2/1740/3602/3610/127
Abdominal painGastrointestinal disorders1/1744/3601/3610/127
Most frequent other events
Showing 10 of 54
Most frequent other events
EventMaraviroc Once Daily + CBV (DB), Then Twice Daily + CBV (OL)Maraviroc Twice Daily + CBV (DB and OL)Efavirenz Once Daily + CBV (DB and OL)Maraviroc Twice Daily + CBV (SP)
NauseaGastrointestinal disorders60/174138/360132/3610/127
DizzinessNervous system disorders25/17462/360116/3610/127
DiarrhoeaGastrointestinal disorders46/17490/360111/3610/127
HeadacheNervous system disorders44/174109/360105/3610/127
Upper respiratory tract infectionInfections and infestations32/17482/36078/3610/127
FatigueGeneral disorders37/17464/36060/3610/127
NasopharyngitisInfections and infestations24/17470/36048/3610/127
CoughRespiratory, thoracic and mediastinal disorders22/17451/36066/3610/127
BronchitisInfections and infestations28/17464/36049/3610/127
Abdominal painGastrointestinal disorders30/17453/36053/3610/127

Baseline characteristics

Age, Customized
Age, Customized(participants)Maraviroc Once Daily + CBV (DB)Maraviroc Twice Daily + CBV (DB and OL)Efavirenz Once Daily + CBV (DB and OL)Total
Less than 18 years0000
18 to 24 years17242566
25 to 34 years47147120314
35 to 44 years73117141331
45 to 54 years295655140
55 to 64 years7141536
Greater than or equal to 65 years1258
Sex: Female, Male
Sex: Female, Male(Participants)Maraviroc Once Daily + CBV (DB)Maraviroc Twice Daily + CBV (DB and OL)Efavirenz Once Daily + CBV (DB and OL)Total
Female44104102250
Male130256259645
08

Study locations

144 sites
  • Pfizer Investigational Site
    Birmingham, Alabama 35233, United States
  • Pfizer Investigational Site
    Birmingham, Alabama 35294-2050, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90211, United States
  • Pfizer Investigational Site
    Los Angeles, California 90022, United States
  • Pfizer Investigational Site
    Los Angeles, California 90048, United States
  • Pfizer Investigational Site
    Los Angeles, California 90069, United States
  • Pfizer Investigational Site
    Newport Beach, California 92663, United States
  • Pfizer Investigational Site
    Oakland, California 94602, United States
  • Pfizer Investigational Site
    Sacramento, California 95825, United States
  • Pfizer Investigational Site
    San Francisco, California 94115-3029, United States
  • Pfizer Investigational Site
    San Francisco, California 94115, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80045, United States
  • Pfizer Investigational Site
    Jacksonville, Florida 32209, United States
  • Pfizer Investigational Site
    Miami Beach, Florida 33139, United States
  • Pfizer Investigational Site
    Miami, Florida 33133, United States
  • Pfizer Investigational Site
    Miami, Florida 33136, United States
  • Pfizer Investigational Site
    Orlando, Florida 32803, United States
  • Pfizer Investigational Site
    Sarasota, Florida 34243, United States
  • Pfizer Investigational Site
    Tampa, Florida 33614, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30308, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60611, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46202, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21201, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02111, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02118-2393, United States
  • Pfizer Investigational Site
    Boston, Massachusetts 02215, United States
  • Pfizer Investigational Site
    Springfield, Massachusetts 01107, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68106, United States
  • Pfizer Investigational Site
    Albany, New York 12208, United States
  • Pfizer Investigational Site
    Brooklyn, New York 11203, United States
  • Pfizer Investigational Site
    Flushing, New York 11355, United States
  • Pfizer Investigational Site
    Manhasset, New York 11030, United States
  • Pfizer Investigational Site
    New York, New York 10016, United States
  • Pfizer Investigational Site
    Huntersville, North Carolina 28078, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45267-0405, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73104-5068, United States
  • Pfizer Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Pfizer Investigational Site
    Columbia, South Carolina 29206, United States
  • Pfizer Investigational Site
    Dallas, Texas 75208, United States
  • Pfizer Investigational Site
    Dallas, Texas 75246, United States
  • Pfizer Investigational Site
    Houston, Texas 77006, United States
  • Pfizer Investigational Site
    Houston, Texas 77098, United States
  • Pfizer Investigational Site
    Annandale, Virginia 22003, United States
  • Pfizer Investigational Site
    Puyallup, Washington 98372, United States
  • Pfizer Investigational Site
    Tacoma, Washington 98405, United States
  • Pfizer Investigational Site
    El Palomar, Provincia de Buenos Aires 1684, Argentina
  • Pfizer Investigational Site
    Neuquen, Provincia de Neuquen Q8300PMB, Argentina
  • Pfizer Investigational Site
    Buenos Aires, Argentina
  • Pfizer Investigational Site
    Ciudad de Buenos Aires, C1202ABB, Argentina
  • Pfizer Investigational Site
    Ciudad de Buenos Aires, C1406FWY, Argentina
  • Pfizer Investigational Site
    Ciudad de Buenos, C1282AEN, Argentina
  • Pfizer Investigational Site
    Provincia de Buenos Aires, Argentina
  • Pfizer Investigational Site
    Provincia de Santa Fe, Argentina
  • Pfizer Investigational Site
    Burwood, New South Wales 2134, Australia
  • Pfizer Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • Pfizer Investigational Site
    Surrey Hills, New South Wales 2010, Australia
  • Pfizer Investigational Site
    Wentworthville, New South Wales 2145, Australia
  • Pfizer Investigational Site
    Herston, Queensland 4029, Australia
  • Pfizer Investigational Site
    Miami, Queensland 4220, Australia
  • Pfizer Investigational Site
    Melbourne, Victoria 3004, Australia
  • Pfizer Investigational Site
    North Fitzroy, Victoria 3068, Australia
  • Pfizer Investigational Site
    South Yarra, Victoria 3141, Australia
  • Pfizer Investigational Site
    Brussels, 1000, Belgium
  • Pfizer Investigational Site
    Brussels, 1200, Belgium
  • Pfizer Investigational Site
    Gent, 9000, Belgium
  • Pfizer Investigational Site
    Leuven, B-3000 Leuven, Belgium
  • Pfizer Investigational Site
    Rio de Janeiro, RJ 20210-030, Brazil
  • Pfizer Investigational Site
    Calgary, Alberta T2R0X7, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • Pfizer Investigational Site
    Edmonton, Alberta T6G 2C8, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V6B 1R3, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • Pfizer Investigational Site
    Vancouver, British Columbia V6Z 2T1, Canada
  • Pfizer Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • Pfizer Investigational Site
    Halifax, Nova Scotia B3H 1V7, Canada
  • Pfizer Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • Pfizer Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5B 1W8, Canada
  • Pfizer Investigational Site
    Toronto, Ontario M5G 2N2, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 4M1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2L 5B1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2W 1T8, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H2X 2P4, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3G 1A4, Canada
  • Pfizer Investigational Site
    Sainte-Foy, Quebec G1V 4G2, Canada
  • Pfizer Investigational Site
    Antella (FI), 50011, Italy
  • Pfizer Investigational Site
    Brescia, 25123, Italy
  • Pfizer Investigational Site
    Milano, 20127, Italy
  • Pfizer Investigational Site
    Modena, 41100, Italy
  • Pfizer Investigational Site
    Roma, 00161, Italy
  • Pfizer Investigational Site
    Roma, 00185, Italy
  • Pfizer Investigational Site
    Torino, 10149, Italy
  • Pfizer Investigational Site
    Del. Tlalpan C.P., Mexico City 14050, Mexico
  • Pfizer Investigational Site
    Del. Tlalpan, C.P., Mexico D.F. 14000, Mexico
  • Pfizer Investigational Site
    Del. Tlalpan, C.P., Mexico D.F. 14080, Mexico
  • Pfizer Investigational Site
    Delegacion Tlalpan C. P, Mexico D.F. 14080, Mexico

Showing the first 100 of 144 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J. No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects. J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7. PubMed 30192390 ↗
  • MacInnes A, Lazzarin A, Di Perri G, Sierra-Madero JG, Aberg J, Heera J, Rajicic N, Goodrich J, Mayer H, Valdez H. Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. HIV Clin Trials. 2011 Jan-Feb;12(1):24-36. doi: 10.1310/hct1201-24. PubMed 21388938 ↗
  • Funderburg N, Kalinowska M, Eason J, Goodrich J, Heera J, Mayer H, Rajicic N, Valdez H, Lederman MM. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. PLoS One. 2010 Oct 6;5(10):e13188. doi: 10.1371/journal.pone.0013188. PubMed 20949133 ↗
  • Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, Dejesus E, Clumeck N, Walmsley S, Ting N, Coakley E, Reeves JD, Reyes-Teran G, Westby M, Van Der Ryst E, Ive P, Mohapi L, Mingrone H, Horban A, Hackman F, Sullivan J, Mayer H. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010 Mar 15;201(6):803-13. doi: 10.1086/650697. PubMed 20151839 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Apr 2007 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 5 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2004
First posted
Dec 7, 2004
Start
Nov 2004
Primary completionActual
Apr 2007
CompletionActual
Dec 2012
Results first posted
Oct 5, 2012
Last update
Oct 9, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00098293
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 7, 2004
Start date
Nov 2004
Primary completion
Apr 2007
Completion
Dec 2012
Results posted
Oct 5, 2012
Last update
Oct 9, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Maraviroc · Zidovudine · Lamivudine

Start the discussion